Upadacitinib will face two main JAK inhibitor competitors – Eli Lilly’s Olumiant and Pfizer’s Xeljanz. Despite excitement surrounding the class, though, these treatments all face a complex ...

The discovery of JAK2V617F has led to the development of selective JAK2 inhibitors for the treatment of PV, ET and PMF. The myeloproliferative disorders polycythaemia vera (PV), essential ...

I-Mab (IMAB) stock gains as an early-stage trial for its gastric cancer therapy givastomig advances in a faster than expected ...

Research by UMass Chan Medical School scientists Sharon Cantor, PhD, and Jenna M. Whalen, PhD, poses a new explanation for how cancer-fighting drugs attack and destroy BRCA1 and BRCA2 tumor cells.

The critical role of EZH2, an essential epigenetic regulator, in cancer progression and treatment is underscored in this new ...

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

K-M curves were utilized to display the survival rate differences, whose significances were evaluated by log-rank tests. A tumor’s TMB was defined as its total count of somatic mutations, and a ...

20 As signalling by these cytokines (except IL-8) are mediated by JAK1, JAK3 and TYK2, it is not surprising that JAK inhibitors may be effective in myositis-associated ILD. Our study is limited by the ...

Cell samples were lysed in RIPA lysis and extraction buffer (ThermoFisher) containing a protease inhibitor cocktail (Sigma ... TNFα concentrations were calculated according to the standard curve.